Semaglutide at 3 months: what the results actually look like

What did @keli.holston actually say?

She's mostly straightforward here. After roughly three months of weekly semaglutide injections, she reports losing 23 pounds total, including 3 pounds in the most recent week. She says she "feels like a different person," is fitting into old clothes, and notices body changes even when the scale stalls. On side effects, she describes weeks two through six as her roughest stretch but says she doesn't have "a ton" of side effects overall.

That's the claim set: 23 pounds in about 13 weeks, meaningful physical change, and a relatively tolerable side effect profile after an early adjustment window. She doesn't make any disease cure claims, doesn't mention doses, and doesn't recommend anyone else take the medication. For a viral weight-loss TikTok, that's a relatively clean content footprint.

Does the science back this up?

Her numbers are plausible but sit near the upper end of what early trial data would predict for a 3-month window. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found participants on 2.4 mg weekly semaglutide lost an average of about 14.9% of body weight over 68 weeks. In the first 12 weeks of that trial, weight loss was substantially lower, typically in the 5-8% range.

If she started at, say, 180-200 lbs, 23 pounds would represent roughly 11-13% body weight loss in 13 weeks, which exceeds the trial average for that timeframe. That doesn't mean it's impossible. Individual variation is real and well-documented. But it's worth knowing that her result, if accurate, appears to be on the faster end of the distribution, not the median experience someone should plan around.

Her observation that the scale wasn't always moving while her body was visibly changing is consistent with what researchers describe as body composition shifts, where fat loss and fluid redistribution don't always register immediately on a standard scale.

What did they get wrong (or right)?

She gets the side effect timeline roughly right. GLP-1 receptor agonist side effects, primarily nausea, vomiting, and gastrointestinal discomfort, tend to peak during dose escalation, which typically spans the first several weeks of treatment. Davies et al. (2021, Diabetes Care) confirmed that GI adverse events were most common early in therapy and diminished over time for most participants. Calling weeks two through six her "most like side effect period" is consistent with that pattern.

What she doesn't address, and what a viewer might miss, is that her experience is not universal. Roughly 44% of participants in STEP 1 reported nausea at some point, and discontinuation due to side effects occurred in about 7% of the semaglutide group. Saying she doesn't have "a ton" of side effects is honest about her own experience, but it could inadvertently set an expectation that most people skate through similarly. Some don't.

She also mispronounces semaglutide consistently as "semi-glutite," which is minor but worth noting because it can make it harder for viewers to search accurate medical information.

What should you actually know?

Three months is genuinely early in a semaglutide trajectory. The full STEP 1 trial ran 68 weeks, and a significant portion of total weight loss came after the 12-week mark once patients reached their maintenance dose. Feeling great at month three is encouraging, but it's not a finish line and it's not representative of the full treatment arc, which includes potential plateaus, dose adjustments, and the question of what happens if and when someone stops.

Semaglutide is a prescription medication. It's not appropriate for everyone, and access through a regulated telehealth provider means a clinician should be evaluating your specific health history before you start. What works well for one person can carry real risks for another, including those with a personal or family history of medullary thyroid carcinoma or pancreatitis.

If you're considering this medication after watching videos like this one, the honest framing is: results vary widely, the first three months are often the most dramatic, and any legitimate provider should be monitoring you throughout, not just handing over a prescription and stepping back.